Fate Therapeutics Company Profile (NASDAQ:FATE)

About Fate Therapeutics (NASDAQ:FATE)

Fate Therapeutics logoFate Therapeutics, Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company's cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity. Its lead clinical program is ProTmune, which is a programmed immuno-regulatory cell therapy. The Company programs immune cells, such as CD34+ cells, Natural Killer (NK) cells and T cells, by utilizing its cell programming approach. Its adoptive cell therapy programs are based on the Company's ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:FATE
  • CUSIP: N/A
  • Web: www.fatetherapeutics.com
Capitalization:
  • Market Cap: $156.44 million
  • Outstanding Shares: 41,386,000
Average Prices:
  • 50 Day Moving Avg: $4.32
  • 200 Day Moving Avg: $3.54
  • 52 Week Range: $1.47 - $5.68
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.90
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $4.4 million
  • Price / Sales: 35.55
  • Book Value: $1.77 per share
  • Price / Book: 2.14
Profitability:
  • EBIDTA: ($31,080,000.00)
  • Net Margins: -740.69%
  • Return on Equity: -112.48%
  • Return on Assets: -58.58%
Debt:
  • Debt-to-Equity Ratio: 0.18%
  • Current Ratio: 3.23%
  • Quick Ratio: 3.23%
Misc:
  • Average Volume: 393,494 shs.
  • Beta: 1.2
  • Short Ratio: 0.37
 

Frequently Asked Questions for Fate Therapeutics (NASDAQ:FATE)

What is Fate Therapeutics' stock symbol?

Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE."

How were Fate Therapeutics' earnings last quarter?

Fate Therapeutics Inc (NASDAQ:FATE) issued its earnings results on Monday, May, 15th. The company reported ($0.24) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.21) by $0.03. The business earned $1.03 million during the quarter, compared to analyst estimates of $1.04 million. Fate Therapeutics had a negative net margin of 740.69% and a negative return on equity of 112.48%. View Fate Therapeutics' Earnings History.

Where is Fate Therapeutics' stock going? Where will Fate Therapeutics' stock price be in 2017?

5 analysts have issued twelve-month price targets for Fate Therapeutics' stock. Their forecasts range from $4.00 to $8.00. On average, they expect Fate Therapeutics' share price to reach $6.40 in the next twelve months. View Analyst Ratings for Fate Therapeutics.

What are analysts saying about Fate Therapeutics stock?

Here are some recent quotes from research analysts about Fate Therapeutics stock:

  • 1. HC Wainwright analysts commented, "With FDA clearing the Investigational New Drug application (IND) for FATE-NK100, we believe Fate made considerable progress to advance its adaptive natural killer (NK) cell program. As the first program of its type, we believe there could have been considerable delays, but we are encouraged by the FDA's decision and would expect similar regulatory approvals in Canada and the UK in the coming quarter. Fate intends to begin its Phase 1 trial in patients with advanced acute myeloid leukemia (AML) with an accelerated doseescalation scheme, agreed to by the FDA, which would employ a single patient at each of four dose levels, provided no dose-limiting toxicities are observed. Once the target therapeutic dose has been safely reached, Fate intends to dose six additional patients. We expect Fate's collaborator at the University of Minnesota (UMN) will be able to enroll this trial briskly and we would expect to see data presented at a medical forum in 2H17. We believe investigators will be looking for a 30% complete response rate, in other words, at least as good as UMN was seeing with its own research. In addition to response rate, Fate will look at disease free survival, minimal residual disease, and persistence. We expect Fate to explore NK100 in solid tumors, submitting a protocol evaluating NK100 in gynecologic malignancies, targeting a mid-2017 start. Separately, we expect NK100 to be evaluated in a combination study with its own IND; we expect a submission in the next couple months. Although we do not include NK100 in our valuation, we believe that positive clinical data could drive significant upside." (3/20/2017)
  • 2. BMO Capital Markets analysts commented, "We are raising our price target to $7 from $4, following 4Q16 earnings that underlined growing interesting in Fate's earlier stage assets, NK100 and iPSC. Our DCF valuation increases as we assign value for these therapies to continue revenue growth beyond ProTmune. We expect ProTmune Phase I interim data in mid-2017 and NK100 to enroll its first AML patient in 2Q17. Fate's hnCD16-iNK could start human trials by early 2018. While we see tremendous potential in the NK100 and iPSC platforms, we wait for clinical validation before including them in our model." (3/17/2017)
  • 3. According to Zacks Investment Research, "Fate Therapeutics, Inc. is a biopharmaceutical company. The company focused on the discovery and development of adult stem cell modulators to treat hematologic malignancies, lysosomal storage disorders and muscular dystrophies. Fate Therapeutics, Inc. is headquartered in San Diego, California. " (3/7/2017)

Are investors shorting Fate Therapeutics?

Fate Therapeutics saw a decrease in short interest in the month of April. As of April 13th, there was short interest totalling 322,583 shares, a decrease of 11.5% from the March 31st total of 364,566 shares. Based on an average daily volume of 200,042 shares, the days-to-cover ratio is currently 1.6 days.

Who are some of Fate Therapeutics' key competitors?

Who owns Fate Therapeutics stock?

Fate Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (10.61%), EcoR1 Capital LLC (6.13%), Polaris Venture Management Co. V L.L.C. (5.98%), Kingdon Capital Management L.L.C. (4.14%), Redmile Group LLC (3.43%) and Vanguard Group Inc. (2.79%). Company insiders that own Fate Therapeutics stock include Chris Storgard and William H Rastetter. View Institutional Ownership Trends for Fate Therapeutics.

Who sold Fate Therapeutics stock? Who is selling Fate Therapeutics stock?

Fate Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Kingdon Capital Management L.L.C.. View Insider Buying and Selling for Fate Therapeutics.

Who bought Fate Therapeutics stock? Who is buying Fate Therapeutics stock?

Fate Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, Vanguard Group Inc., Wells Fargo & Company MN, Goldman Sachs Group Inc., Renaissance Technologies LLC, Neuberger Berman Group LLC, Morgan Stanley and TFS Capital LLC. Company insiders that have bought Fate Therapeutics stock in the last two years include Chris Storgard and William H Rastetter. View Insider Buying and Selling for Fate Therapeutics.

How do I buy Fate Therapeutics stock?

Shares of Fate Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Fate Therapeutics stock cost?

One share of Fate Therapeutics stock can currently be purchased for approximately $3.78.

Analyst Ratings

Consensus Ratings for Fate Therapeutics (NASDAQ:FATE) (?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $6.40 (69.31% upside)

Analysts' Ratings History for Fate Therapeutics (NASDAQ:FATE)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/16/2017WedbushReiterated RatingOutperform$7.00HighView Rating Details
3/20/2017HC WainwrightLower Price TargetBuy$8.00 -> $6.00LowView Rating Details
3/18/2017Roth CapitalSet Price TargetBuy$8.00LowView Rating Details
3/17/2017BMO Capital MarketsBoost Price TargetBuy$7.00MediumView Rating Details
6/21/2016Leerink SwannReiterated RatingOutperform$4.00N/AView Rating Details
5/10/2016Wells Fargo & CoReiterated RatingBuyN/AView Rating Details
11/5/2015Cowen and CompanyReiterated RatingOutperformN/AView Rating Details
10/6/2015Raymond James Financial, Inc.Initiated CoverageOutperform$8.00N/AView Rating Details
(Data available from 5/23/2015 forward)

Earnings

Earnings History for Fate Therapeutics (NASDAQ:FATE)
Earnings by Quarter for Fate Therapeutics (NASDAQ:FATE)
Earnings History by Quarter for Fate Therapeutics (NASDAQ:FATE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/15/2017Q1 2017($0.21)($0.24)$1.04 million$1.03 millionViewN/AView Earnings Details
3/16/2017Q4 2016($0.28)($0.21)$1.06 million$1.03 millionViewN/AView Earnings Details
11/7/2016Q316($0.29)($0.27)$1.05 million$1.03 millionViewListenView Earnings Details
8/8/2016Q216($0.32)($0.29)$1.02 million$1.03 millionViewN/AView Earnings Details
5/9/2016Q116($0.25)($0.29)$0.84 million$1.32 millionViewN/AView Earnings Details
3/3/2016Q415($0.27)($0.26)$0.58 million$1.08 millionViewN/AView Earnings Details
11/3/2015Q315($0.32)($0.24)$0.46 million$1.03 millionViewN/AView Earnings Details
8/5/2015Q215($0.39)($0.33)$0.31 million$0.33 millionViewN/AView Earnings Details
5/7/2015Q115($0.34)($0.38)ViewListenView Earnings Details
3/12/2015Q414($0.31)($0.30)ViewListenView Earnings Details
11/11/2014Q3 2014($0.29)($0.30)ViewN/AView Earnings Details
8/12/2014Q214($0.36)($0.30)ViewN/AView Earnings Details
5/13/2014Q114($0.32)($0.34)ViewN/AView Earnings Details
3/17/2014Q413($0.27)($0.29)ViewN/AView Earnings Details
11/13/2013Q3($0.32)($4.81)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Fate Therapeutics (NASDAQ:FATE)
2017 EPS Consensus Estimate: ($1.00)
2018 EPS Consensus Estimate: ($1.12)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.24)($0.22)($0.23)
Q2 20172($0.25)($0.24)($0.25)
Q3 20172($0.26)($0.25)($0.26)
Q4 20172($0.27)($0.26)($0.27)
Q1 20181($0.21)($0.21)($0.21)
Q2 20181($0.27)($0.27)($0.27)
Q3 20181($0.30)($0.30)($0.30)
Q4 20181($0.34)($0.34)($0.34)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Fate Therapeutics (NASDAQ:FATE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Fate Therapeutics (NASDAQ:FATE)
Insider Ownership Percentage: 13.66%
Institutional Ownership Percentage: 47.08%
Insider Trades by Quarter for Fate Therapeutics (NASDAQ:FATE)
Institutional Ownership by Quarter for Fate Therapeutics (NASDAQ:FATE)
Insider Trades by Quarter for Fate Therapeutics (NASDAQ:FATE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/23/2016Chris StorgardInsiderBuy37,593$2.66$99,997.38View SEC Filing  
11/23/2016William H RastetterDirectorBuy375,939$2.66$999,997.74View SEC Filing  
6/12/2014Peter D FlynnInsiderSell6,488$7.00$45,416.00View SEC Filing  
6/10/2014Peter D FlynnInsiderSell3,305$7.00$23,135.00View SEC Filing  
5/1/2014Peter D FlynnInsiderSell9,793$7.07$69,236.51View SEC Filing  
4/4/2014Peter D FlynnInsiderSell5,889$8.00$47,112.00View SEC Filing  
4/2/2014Christian WeyerInsiderSell10,000$9.02$90,200.00View SEC Filing  
4/1/2014J Scott WolchkoInsiderSell20,000$9.64$192,800.00View SEC Filing  
3/31/2014Daniel D ShoemakerCTOSell8,653$9.86$85,318.58View SEC Filing  
10/4/2013John MendleinDirectorBuy16,667$6.00$100,002.00View SEC Filing  
10/4/2013Venture Fund Vi Lp ArchMajor ShareholderBuy833,333$6.00$4,999,998.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Fate Therapeutics (NASDAQ:FATE)
Latest Headlines for Fate Therapeutics (NASDAQ:FATE)
Source:
DateHeadline
americanbankingnews.com logoFate Therapeutics Inc Forecasted to Post Q2 2017 Earnings of ($0.25) Per Share (FATE)
www.americanbankingnews.com - May 18 at 8:20 AM
nasdaq.com logoFate Therapeutics Reports First Quarter 2017 Financial Results - Nasdaq
www.nasdaq.com - May 17 at 5:07 PM
americanbankingnews.com logoFate Therapeutics Inc (FATE) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPS
www.americanbankingnews.com - May 16 at 12:26 PM
finance.yahoo.com logoFate Therapeutics reports 1Q loss
finance.yahoo.com - May 16 at 11:47 AM
americanbankingnews.com logoFate Therapeutics Inc (FATE) Receives Outperform Rating from Wedbush
www.americanbankingnews.com - May 16 at 8:14 AM
finance.yahoo.com logoFate Therapeutics Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 15 at 4:49 PM
americanbankingnews.com logo Brokerages Expect Fate Therapeutics Inc (FATE) Will Post Earnings of -$0.21 Per Share
www.americanbankingnews.com - May 12 at 12:02 AM
globenewswire.com logoFate Therapeutics Announces FDA Clearance of Investigational New Drug Application for FATE-NK100 in Advanced ... - GlobeNewswire (press release)
globenewswire.com - May 10 at 10:17 PM
streetinsider.com logoFate Therapeutics (FATE) Says FDA Cleared IND for FATE-NK100 in Advanced Solid Tumors
www.streetinsider.com - May 10 at 8:47 AM
finance.yahoo.com logoFate Therapeutics Announces FDA Clearance of Investigational New Drug Application for FATE-NK100 in Advanced Solid Tumors
finance.yahoo.com - May 10 at 8:47 AM
globenewswire.com logoFate Therapeutics to Webcast Conference Call Reporting First Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - May 9 at 9:13 AM
finance.yahoo.com logoFate Therapeutics to Webcast Conference Call Reporting First Quarter 2017 Financial Results
finance.yahoo.com - May 8 at 4:57 PM
americanbankingnews.com logoFate Therapeutics Inc (FATE) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 2 at 4:56 PM
americanbankingnews.com logoFate Therapeutics (FATE) Receiving Somewhat Negative Media Coverage, AlphaOne Reports
www.americanbankingnews.com - May 1 at 4:30 PM
finance.yahoo.com logoFate Therapeutics to Kick-Off 2017 Annual Meeting of International ... - Yahoo Finance
finance.yahoo.com - April 28 at 7:40 AM
americanbankingnews.com logoFate Therapeutics (FATE) Earns Daily Media Impact Rating of 0.34
www.americanbankingnews.com - April 27 at 11:06 PM
globenewswire.com logoFate Therapeutics to Kick-Off 2017 Annual Meeting of International Society for Stem Cell Research with Off-the-Shelf ... - GlobeNewswire (press release)
globenewswire.com - April 27 at 5:41 PM
americanbankingnews.com logoFate Therapeutics Inc (FATE) Short Interest Update
www.americanbankingnews.com - April 27 at 12:10 PM
finance.yahoo.com logoFate Therapeutics to Kick-Off 2017 Annual Meeting of International Society for Stem Cell Research with Off-the-Shelf Natural Killer Cell Cancer Immunotherapy Focus Session
finance.yahoo.com - April 27 at 11:25 AM
americanbankingnews.com logoFate Therapeutics (FATE) Earns Daily Media Sentiment Score of -0.22
www.americanbankingnews.com - April 23 at 9:06 AM
americanbankingnews.com logoZacks: Analysts Anticipate Fate Therapeutics Inc (FATE) to Announce -$0.21 EPS
www.americanbankingnews.com - April 21 at 8:27 AM
finance.yahoo.com logoFate Therapeutics to Present at the 5th Annual Cell & Gene Therapy Investor Day
finance.yahoo.com - April 20 at 12:00 PM
americanbankingnews.com logoFate Therapeutics (FATE) Given Daily Media Impact Rating of 0.42
www.americanbankingnews.com - April 19 at 11:37 AM
finance.yahoo.com logoETFs with exposure to Fate Therapeutics, Inc. : April 7, 2017
finance.yahoo.com - April 7 at 5:05 PM
americanbankingnews.com logoFate Therapeutics Inc (FATE) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - April 5 at 3:46 PM
finance.yahoo.com logoSurging Earnings Estimates Signal Good News for Fate Therapeutics (FATE)
finance.yahoo.com - March 28 at 11:51 AM
americanbankingnews.com logoHC Wainwright Lowers Fate Therapeutics Inc (FATE) Price Target to $6.00
www.americanbankingnews.com - March 24 at 11:28 AM
finance.yahoo.com logoFATE THERAPEUTICS INC Financials
finance.yahoo.com - March 23 at 5:38 PM
americanbankingnews.com logoFate Therapeutics Inc (FATE) PT Lowered to $6.00 at HC Wainwright
www.americanbankingnews.com - March 20 at 7:55 PM
americanbankingnews.com logoFate Therapeutics Inc (FATE) PT Lowered to $6.00 at HC Wainwright
www.americanbankingnews.com - March 20 at 7:55 PM
americanbankingnews.com logoFate Therapeutics Inc to Post FY2021 Earnings of $2.66 Per Share, Wedbush Forecasts (FATE)
www.americanbankingnews.com - March 20 at 12:23 PM
seekingalpha.com logoFate Therapeutics' (FATE) CEO Scott Wolchko on Q4 2016 Results ... - Seeking Alpha
seekingalpha.com - March 17 at 5:27 PM
finance.yahoo.com logoA Data-Rich Year Has Analysts Accepting Their Fate Therapeutics Trade
finance.yahoo.com - March 17 at 5:26 PM
americanbankingnews.com logoFate Therapeutics Inc (FATE) Given “Outperform” Rating at Wedbush
www.americanbankingnews.com - March 17 at 11:19 AM
reuters.com logoBRIEF-Fate Therapeutics qtrly net loss per common share $ 0.21
www.reuters.com - March 16 at 11:29 PM
cnbc.com logoFate Therapeutics reports 4Q loss
www.cnbc.com - March 16 at 6:27 PM
finance.yahoo.com logoFate Therapeutics Reports Fourth Quarter 2016 Financial Results
finance.yahoo.com - March 16 at 6:27 PM
biz.yahoo.com logoFATE THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh
biz.yahoo.com - March 16 at 6:27 PM
streetinsider.com logoFate Therapeutics (FATE) Receieves FDA Clearance of IND Application for FATE-NK100 Natural Killer Cell Cancer Immunotherapy
www.streetinsider.com - March 13 at 11:48 AM
us.rd.yahoo.com logoFate Therapeutics Announces FDA Clearance of Investigational New Drug Application for FATE-NK100 Natural Killer Cell Cancer Immunotherapy
us.rd.yahoo.com - March 13 at 11:48 AM
us.rd.yahoo.com logo8:01 am Fate Therapeutics announces that the FDA has cleared an investigational new drug application for FATE-NK100, the Co's first-in-class adaptive memory natural killer cell product candidate
us.rd.yahoo.com - March 13 at 11:48 AM
finance.yahoo.com logoFate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2016 Financial Results
finance.yahoo.com - March 9 at 5:38 PM
finance.yahoo.com logoExplosive Stocks Under $10
finance.yahoo.com - March 7 at 4:58 PM
finance.yahoo.com logoFate Therapeutics to Highlight Natural Killer Cell Programs and Engineered Pluripotent Cell Platform for Off-the-Shelf Cancer Immunotherapy at the 2017 AACR Annual Meeting
finance.yahoo.com - March 2 at 5:24 PM
globenewswire.com logoFate Therapeutics to Present at Two Upcoming Conferences in March - GlobeNewswire (press release)
globenewswire.com - March 1 at 4:52 PM
finance.yahoo.com logoFate Therapeutics to Present at Two Upcoming Conferences in March
finance.yahoo.com - March 1 at 4:52 PM
finance.yahoo.com logoFate Therapeutics and Regents of the University of Minnesota Expand Research Collaboration for Clinical Translation of Engineered iPSC-Derived Natural Killer Cell Cancer Immunotherapy
finance.yahoo.com - February 27 at 7:22 PM
finance.yahoo.com logo8:08 am Fate Therapeutics expands its research collaboration w/ the University of Minnesota to initiate the clinical translation an of an off-the-shelf targeted natural killer cell cancer immunotherapy derived from an engineered induced plu
finance.yahoo.com - February 27 at 7:22 PM
fool.com logoBetter Buy: Organovo Holdings, Inc. vs. United Therapeutics Corporation
www.fool.com - February 22 at 5:23 PM
nasdaq.com logoForget Gilead, Buy These 5 Biotech Stocks Instead - Nasdaq - Nasdaq
www.nasdaq.com - February 13 at 5:58 PM

Social

Fate Therapeutics (FATE) Chart for Tuesday, May, 23, 2017

This page was last updated on 5/23/2017 by MarketBeat.com Staff